Ticker Details
Arbutus Biopharma Corporation Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
IPO Date:	October 31, 2008
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$859.29M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.12 | 3.19%
Avg Daily Range (30 D):	$0.09 | 2.12%
Avg Daily Range (90 D):	$0.10 | 2.32%

Institutional Daily Volume
Avg Daily Volume:	.91M
Avg Daily Volume (30 D):	1.43M
Avg Daily Volume (90 D):	1.82M

Trade Size
Avg Trade Size (Sh.):	209
Avg Trade Size (Sh.) (30 D):	155
Avg Trade Size (Sh.) (90 D):	155

Institutional Trades
Total Institutional Trades:	370
Avg Institutional Trade:	$1.59M
Avg Institutional Trade (30 D):	$2.14M
Avg Institutional Trade (90 D):	$1.56M
Avg Institutional Trade Volume:	.43M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.62M
Avg Closing Trade (30 D):	$1.27M
Avg Closing Trade (90 D):	$1.23M
Avg Closing Volume:	420.73K

News

Mar 5, 2026 @ 7:42 PM 9 Biotech Stocks Trading Far Below Fair Value With... Source: David Wagner

Mar 4, 2026 @ 1:14 PM Moderna's $950 Million Settlement Clears Legal Ove... Source: Vandana Singh

Feb 20, 2025 @ 8:22 AM Will Moderna Stock Drop to $25? 1 Wall Street Anal... Source: Eric Volkman

Jun 13, 2024 @ 9:12 AM Ultragenyx (RARE) Moves 7.8% Higher: Will This Str... Source: Zacks Equity Research

Jun 6, 2024 @ 3:15 PM Treatment with Arbutus’ Imdusiran and VTP-3... Source: Arbutus Biopharma Corporation

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.84	$.88	$-.01
Diluted EPS	$.83	$.87	$-.01
Revenue	$191.45M	$179.13M	$1.05M
Gross Profit
Net Income / Loss	$160.72M	$169.7M	$-3.76M
Operating Income / Loss	$156.45M	$168.91M	$-5.29M
Cost of Revenue
Net Cash Flow	$-13.37M	$5.7M	$-4.4M
PE Ratio

Splits
Nov 04, 2010	1:5